August 2026
1. ALBAYRAK E, Hizarci Bal R, Altan M, Yazici S, et al
   Incidence, Clinicopathological Features, and Survival Impact of Incidental Prostate Cancer in Radical Cystoprostatectomy: A Single-Center Analysis.
   Urol Int. 2026 Aug 20:1-11. doi: 10.1159/000553544.
   

   >> Share

   
   
2. STEENBOCK O, Rieger C, Heidenreich J, Paffenholz P, et al
   How Often are druggable mutations detectable in Metastatic Castration Resistant Prostate Cancer?
   Urol Int. 2026 Aug 13:1. doi: 10.1159.
   

   >> Share

   
   July 2026
3. MELCHIOR F, Koett M, Aigner G, Schroffenegger J, et al
   Real-World Use of Prolaris(R) to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance.
   Urol Int. 2026 Jul 17:1-14. doi: 10.1159/000553659.
   

   >> Share

   
   June 2026
4. SHEN B, Wang F
   Precision Nodal Staging in Intermediate-Risk Prostate Cancer: A Narrative Review of Molecular Imaging.
   Urol Int. 2026 Jun 12:1-19. doi: 10.1159/000552660.
   

   >> Share

   
   
5. BEHNEL N, Engelage L, Lumiani A, Buchner A, et al
   Transition Zone PSA Density Does Not Improve Detection of Clinically Significant Prostate Cancer Over Whole-Gland PSAD: A Volume-Stratified Analysis in 3,958 Patients.
   Urol Int. 2026 Jun 4:1-15. doi: 10.1159/000552900.
   

   >> Share

   
   
6. ALBARGHOUTH MH, Leeder M, Leucht K, Seifert P, et al
   Diagnostic Value of PSMA-PET/CT for the Detection of Pelvic Lymph Node Metastasis in Intermediate and High-Risk Prostate Cancer.
   Urol Int. 2026 Jun 4:1-14. doi: 10.1159/000552672.
   

   >> Share

   
   April 2026
7. SCHOSTAK M, Peklo E, Peters I, Machtens S, et al
   Parameters predicting Recurrence after Focal Therapy for Prostate Cancer: Insights from a Multicenter Surveillance Database.
   Urol Int. 2026 Apr 2:1-20. doi: 10.1159/000551632.
   

   >> Share

   
   February 2026
8. DONCK E, Fede Spicchiale C, Yang T, Bou Kheir G, et al
   Pelvic lymph node dissection during radical prostatectomy for prostate cancer: harms versus benefits.
   Urol Int. 2026 Feb 2:1-21. doi: 10.1159/000550027.
   

   >> Share

   
   January 2026
9. AYDOGDU C, Urban F, Berg E, Gotz M, et al
   Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study.
   Urol Int. 2026 Jan 19:1-20. doi: 10.1159/000550580.
   

   >> Share

   
   
10. POLAT H, Sungur U, Eksi M, Guner E, et al
    The Relationship of Chronic Inflammation in Prostate Biopsies with International Society of Urological Pathology Score Upgrade after Radical Prostatectomy.
    Urol Int. 2026;110:55-61.
    

    >> Share

    
    
11. ELLEISY M, Resch I, Yurdakul O, Hubner NA, et al
    Acute Kidney Injury in a Cancer Patient Exposed to Relugolix and Abiraterone.
    Urol Int. 2026;110:198-201.
    

    >> Share

    
    November 2025
12. GORGEL SN, Akin Y, Yorulmaz EM, Donmez K, et al
    Predictive Value of Node-RADS for Lymph Node Involvement in Prostate Cancer: A Matched Cohort Study.
    Urol Int. 2025 Nov 3:1-19. doi: 10.1159/000549303.
    

    >> Share

    
    October 2025
13. RISCH J, Hugelmann K, Buck L, von Knobloch HC, et al
    Readability of Prostate Cancer Patient Education Materials: A Comprehensive Assessment Using Readability Metrics.
    Urol Int. 2025 Oct 9:1-15. doi: 10.1159/000548884.
    

    >> Share

    
    August 2025
14. LUO H, Liao G, Liu Y
    Efficacy of Neoadjuvant Hormone Therapy Combined with Radical Prostatectomy in Improving Oncological Outcomes for Patients with cT3 Prostate Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2025 Aug 13:1-37. doi: 10.1159/000547875.
    

    >> Share

    
    July 2025
15. PHILIPPOU C, Gloger S, Ubrig B, Bitterlich N, et al
    Estimating Bone Metastasis Risk in Prostate Cancer: A Three-Parameter Model using BSP, ISUP Grading, and Tumor Progression.
    Urol Int. 2025 Jul 25:1-34. doi: 10.1159/000547556.
    

    >> Share

    
    June 2025
16. PINA-VAZ T, Costa Silva A, Costa G, Goncalves M, et al
    Sexually Transmitted Infections in Prostate Cancer: A Prospective Multicenter Analysis.
    Urol Int. 2025 Jun 21:1-13. doi: 10.1159/000545208.
    

    >> Share

    
    May 2025
17. NIRAZUKA A, Nakayama A, Inoue M, Tsujioka H, et al
    Impact of an Early Prostate-Specific Antigen Response on Biochemical Progression During Upfront Androgen Receptor Signal Inhibitor Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Urol Int. 2025 May 22:1-18. doi: 10.1159/000546327.
    

    >> Share

    
    April 2025
18. BORKOWETZ A, Wullich B, Saar M, Schmidt-Hegemann N, et al
    Treatment strategies in oligo-metastatic prostate cancer - a nation-wide survey.
    Urol Int. 2025 Apr 14:1-20. doi: 10.1159/000545630.
    

    >> Share

    
    January 2025
19. FIORELLO N, Zucchi A, Gregori F, Romei G, et al
    Urinary Leakage after Robot-Assisted Radical Prostatectomy: Is Always Predictive of Functional Results?
    Urol Int. 2025;109:68-73.
    

    >> Share

    
    
20. ELLEISY M, Drager DL, Zettl H, Hakenberg OW, et al
    COVID-19 Pandemic Impact on Uro-Oncological Disease Outcomes at a German Referral Center.
    Urol Int. 2025;109:135-145.
    

    >> Share

    
    
21. SPACHMANN PJ, Witt D, Breyer J, Denzinger S, et al
    Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin.
    Urol Int. 2025;109:146-150.
    

    >> Share

    
    
22. ELLEISY M, Zettl H, Drager DL, Hakenberg OW, et al
    The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center Experience.
    Urol Int. 2025;109:361-371.
    

    >> Share

    
    
23. BAHLBURG H, Bahlburg H, Rausch P, Silberg M, et al
    Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?
    Urol Int. 2025;109:501-507.
    

    >> Share

    
    
24. SCHMITZ-DRAGER BJ, Schmitz-Drager BJ, Bismarck E, Ebert T, et al
    Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN).
    Urol Int. 2025;109:519-527.
    

    >> Share

    
    October 2024
25. JI G, Liu F, Chen Z, Peng J, et al
    Correlation of magnetic resonance imaging and computed tomography with biological factor expression and lymph node metastasis in aggressive prostate cancer.
    Urol Int. 2024 Oct 25:1-8. doi: 10.1159/000541953.
    

    >> Share

    
    
26. YU J, Zhou K, Wang J, Mao L, et al
    Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration?resistant prostate cancer: a single-center, open-label study.
    Urol Int. 2024 Oct 15:1-13. doi: 10.1159/000541929.
    

    >> Share

    
    
27. OPPOLZER IA, Schnabel MJ, Hammer S, Zilles H, et al
    Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer.
    Urol Int. 2024 Oct 3:1-15. doi: 10.1159/000541753.
    

    >> Share

    
    September 2024
28. BULBUL O, Nak D, Goksel S
    Prediction of lesion-based treatment response after two cycles of Lu-177 PSMA treatment in metastatic castration-resistant prostate cancer using machine learning.
    Urol Int. 2024 Sep 30:1-12. doi: 10.1159/000541628.
    

    >> Share

    
    August 2024
29. OBERNEDER M, Henzler T, Kriegmair M, Vag T, et al
    Prediction of clinically significant prostate cancer using multi parametric MRI, biparametric MRI and clinical parameters.
    Urol Int. 2024 Aug 31. doi: 10.1159/000541152.
    

    >> Share

    
    May 2024
30. GLOGER S, Paulics L, Philippou C, Philippou S, et al
    Perioperative rates of incidental prostate cancer after aquablation and holmium laser enucleation of the prostate (HoLEP).
    Urol Int. 2024 May 27. doi: 10.1159/000539014.
    

    >> Share

    
    March 2024
31. SIMSEK A, Celen S, Duran MB, Kucuker K, et al
    THE DIAGNOSTIC ACCURACY OF A COMBINATION OF PREOPERATIVE 68-Ga PSMA PET/CT AND MULTIPARAMETRIC MRI IN LOCALIZED PROSTATE CANCER.
    Urol Int. 2024 Mar 13. doi: 10.1159/000538061.
    

    >> Share

    
    
32. HU S, Xiong X, Qiu S, Li J, et al
    Comparing efficacies of different exercises on androgen deprivation therapy adverse effects in prostate cancer patients: a network meta-analysis.
    Urol Int. 2024 Mar 2. doi: 10.1159/000538114.
    

    >> Share

    
    January 2024
33. RIEDEL A, Michael M, Grunberg J, Mehralivand S, et al
    The role of multiparametric MRI (mpMRI) in the prediction of adverse prostate cancer pathology in radical prostatectomy specimen.
    Urol Int. 2024 Jan 19. doi: 10.1159/000536256.
    

    >> Share

    
    
34. WU S, Feldman AS, Lin SX, Kim MM, et al
    Estimated Prostate Volume by Semiautomatic Segmentation of MRI Is More Accurately Correlated with Radical Prostatectomy Specimen Weight than the Volume Calculated by Ellipsoid Formula.
    Urol Int. 2024;108:35-41.
    

    >> Share

    
    
35. SIGG S, Arnold W, Grossmann NC, Baumeister P, et al
    Why Do Men Reject Adjuvant Radiotherapy following Radical Prostatectomy? A Systematic Survey.
    Urol Int. 2024;108:211-218.
    

    >> Share

    
    
36. FARZAT M, Wagenlehner FM
    How Might the Number of Lymph Nodes Removed during RARP Impact the Postoperative Outcomes?
    Urol Int. 2024;108:175-182.
    

    >> Share

    
    
37. FERRANDINO MN, Espino G, Young M, Bodden E, et al
    Initial Experience with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence following Radical Prostatectomy: A Report of 2 Cases.
    Urol Int. 2024;108:574-577.
    

    >> Share

    
    November 2023
38. CANKAYA S, Caylan AE, Aydin F, Ucar M, et al
    Correlation between prostate cancer positive cores and 68Ga-PSMA distribution in prostate gland.
    Urol Int. 2023 Nov 28. doi: 10.1159/000535466.
    

    >> Share

    
    
39. CUI Y, Zhao J, Sun Y
    The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions.
    Urol Int. 2023 Nov 27:1-6. doi: 10.1159/000534597.
    

    >> Share

    
    
40. SENEL S, Koudonas A, Uzun E, Ceviz K, et al
    The Value of Prostate-Specific Antigen Density in Combination with Lesion Diameter for the Accuracy of Prostate Cancer Prediction in Prostate Imaging-Reporting and Data System 3 Prostate Lesions.
    Urol Int. 2023 Nov 20:1-6. doi: 10.1159/000534805.
    

    >> Share

    
    
41. SIKIC D, Fiebig C, Wullich B, Wolff I, et al
    Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE Study.
    Urol Int. 2023 Nov 6:1-10. doi: 10.1159/000534486.
    

    >> Share

    
    January 2023
42. SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
    Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
    Urol Int. 2023;107:841-847.
    

    >> Share

    
    
43. SCARCIA M, Moretto S, Zazzara M, Alba S, et al
    Robot-Assisted Extraperitoneal Radical Prostatectomy for Giant Multilocular Prostatic Cystadenoma: A Case Report and Literature Review.
    Urol Int. 2023;107.
    

    >> Share

    
    
44. STOLZENBACH LF, Fankhauser CD, Mattei A, Wurnschimmel C, et al
    Solitary Fibrous Tumor of the Prostate Treated with Frozen-Section Supported Robot-Assisted Nerve-Sparing Radical Prostatectomy.
    Urol Int. 2023;107.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share